SAB Biotherapeutics announced that Alexandra Kropotova, MD, Executive Vice President and Chief Medical Officer, will deliver a presentation at the Biotech Showcase in San Francisco on Tuesday, Jan. 10 at 2:30 p.m. PST. Dr. Kropotova’s presentation, titled: Next Generation Biologics in Immunology: Solution for Complex Diseases, will discuss the latest innovations and treatment pathways in immunology, including an overview of SAB’s novel DiversitAb platform. DiversitAb is the only platform in the world that produces fully-human, broadly neutralizing, polyclonal antibodies utilizing transchromosomic cows. Dr. Kropotova will also present data from completed clinical trials that indicate SAB’s polyclonal antibody therapies can provide long-lasting efficacy against numerous highly mutating pathogens or multiple targets or pathways at once.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SABS:
- SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes
- SAB Biotherapeutics’ CMO Alexandra Kropotova to Deliver Presentation on Next Generation Biologics in Immunology at Biotech Showcase
- SAB Biotherapeutics announces results from project using DiversitAb platform
- SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases
- SAB Biotherapeutics CMO Selected to Present at the January 2023 Biotech Showcase in San Francisco
